Table 1.
Demographic and Clinical Characteristics of Auto- and Allo-HSCT Survivors.
| Allo-HSCT (n=36) | Auto-HSCT (n=13) | p | |
|---|---|---|---|
| Age, years | 49.4 (12.8) | 54.8 (11.5) | 0.197 |
| Female/male | 21 (58.7%)/15 (41.7%) | 5 (38.5%)/8 (61.5%) | 0.218 |
| Time elapsed from HSCT | 49.5 (8-199) | 43 (1-121) | 0.150 |
| Diagnosis | |||
| Acute leukemia | 20 (55.5%) | 0 | |
| Myelodysplastic syndrome | 9 (25.0%) | 0 | |
| Multiple myeloma | 0 | 7 (53.8%) | |
| Malignant lymphoma | 2 (5.6%) | 6 (46.2%) | |
| Other | 5 (13.9%) | 0 | |
| Clinical laboratory data | |||
| CRP (mg/dL) | 0.1 (±0.1) | 0.1 (±0.1) | 0.658 |
| Albumin (g/dL) | 4.1 (±0.3) | 4.3 (±0.2) | 0.189 |
| Total protein (g/dL) | 6.7 (±0.4) | 6.7 (±0.5) | 0.695 |
| Hemoglobin (g/dL) | 12.7 (±1.3) | 12.5 (±2.2) | 0.76 |
| White cell (number, 103/μL) | 5.6 (±1.9) | 4.7 (±1.9) | 0.138 |
| Neutrophils (number, 103/μL) | 3.1 (±1.4) | 2.3 (±1.3) | 0.081 |
| Lymphocytes (number, 103/μL) | 1.9 (±0.8) | 1.9 (±0.7) | 0.859 |
| Platelet (number, 103/μL) | 205.0 (±55.8) | 184.7 (±53.5) | 0.271 |
| Comorbidity | 0.84 | ||
| None | 21 (58.3%) | 8 (61.5%) | |
| Yes | 15 (41.7%) | 5 (38.5%) | |
| Stem cell source | |||
| Bone marrow | 23 (63.9%) | NA | |
| Cord blood | 9 (25.0%) | NA | |
| Peripheral blood stem cell | 4 (11.1%) | 13 (100%) | |
| Donor type | NA | ||
| HLA-mismatched/unrelated | 13 (36.1%) | ||
| HLA-matched/related | 11 (30.6%) | ||
| HLA-matched/unrelated | 10 (27.8%) | ||
| HLA-mismatched/related | 1 (2.8%) | ||
| History of aGVHD | NA | ||
| Yes | 26 (72.2%) | ||
| No | 10 (27.8%) | ||
| cGVHD at survey | NA | ||
| Yes | 8 (22.2%) | ||
| No | 28 (77.8%) | ||
| History of cGVHD | NA | ||
| Yes | 15 (41.7%) | ||
| No | 21 (58.3%) | ||
| On maintenance treatment | NA | ||
| Yes | 5 (38.5%) | ||
| No | 8 (61.5%) |
Values are mean±SD, n (%), or median (range). HSCT: hematopoietic stem cell transplantation, SD: standard deviation, CRP: C-reactive protein, NA: not applicable, HLA: human leukocyte antigen, GVHD: graft versus host disease